PR Newswire·Nov 9, 2026, 4:05 PM ET

PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility

PharmaLogic Holdings Corp. announced a definitive agreement to acquire the CDMO business & Springfield, New Jersey manufacturing facility from Lantheus Holdings, Inc.
The Springfield facility is a state-of-the-art radiopharmaceutical site with a proven track record in theranostic manufacturing, research, & clinical development.
The Springfield team will join Agilera, PharmaLogic's therapeutic CDMO franchise, upon transaction completion.
The deal includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
The acquisition expands PharmaLogic's U.S. capacity to manufacture radiopharmaceutical therapeutics & establishes the first transatlantic CDMO platform for radioligand therapies.
Agilera brings over 15 years of experience supporting radioligand therapy development & currently supplies an alpha therapy to more than 30 countries.
The new platform offers partners an end-to-end solution for radioligand therapies from early clinical development through commercial launch & global supply.
The transaction is subject to regulatory review & customary closing conditions, with both parties continuing to operate independently until closing.
Leerink Partners served as financial advisor to PharmaLogic, while Goodwin Procter LLP served as legal advisor; Solomon Partners Securities LLC & Covington & Burling LLP served as advisors to Lantheus.
Financial terms of the transaction were not disclosed.